SKOR2

Summary

SKOR2 (SKI family transcriptional corepressor 2, HGNC:32695) is a protein-coding gene on chromosome 18q21.1, encoding SKI family transcriptional corepressor 2 (Q2VWA4). Exhibits transcriptional repressor activity.

Enables SMAD binding activity and sequence-specific double-stranded DNA binding activity. Involved in negative regulation of transforming growth factor beta receptor signaling pathway. Located in cytoplasm and nucleus.

Source: NCBI Gene 652991 — RefSeq curated summary.

At a glance

• Gene–disease (curated): nervous system disorder (Limited, GenCC)
• GWAS associations: 9
• Clinical variants (ClinVar): 8 total — 5 pathogenic
• Phenotypes (HPO): 24
• MANE Select transcript: NM_001278063

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32695
Approved symbol	SKOR2
Name	SKI family transcriptional corepressor 2
Location	18q21.1
Locus type	gene with protein product
Status	Approved
Aliases	CORL2, FUSSEL18, Fussel-18
Ensembl gene	ENSG00000215474
Ensembl biotype	protein_coding
OMIM	617138
Entrez	652991

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000400404, ENST00000425639

RefSeq mRNA: 2 — MANE Select: NM_001278063 NM_001037802, NM_001278063

CCDS: CCDS62441, CCDS74222

Canonical transcript exons

ENST00000425639 — 9 exons

Exon	Start	End
ENSE00001664783	47245498	47245561
ENSE00001677627	47230935	47231000
ENSE00001715448	47230459	47230557
ENSE00003575001	47244908	47244982
ENSE00003745534	47219943	47220010
ENSE00003792160	47212086	47212151
ENSE00003792439	47251374	47251660
ENSE00003797622	47206169	47206892
ENSE00003798699	47246571	47249230

Expression profiles

Bgee: expression breadth broad, 18 present calls, max score 79.07.

Top tissues by expression

127 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.07	gold quality
sural nerve	UBERON:0015488	71.08	gold quality
hindlimb stylopod muscle	UBERON:0004252	49.70	silver quality
olfactory segment of nasal mucosa	UBERON:0005386	47.39	gold quality
colonic epithelium	UBERON:0000397	44.83	gold quality
bone marrow cell	CL:0002092	43.78	gold quality
right hemisphere of cerebellum	UBERON:0014890	42.59	silver quality
primary visual cortex	UBERON:0002436	41.84	gold quality
cortical plate	UBERON:0005343	39.94	gold quality
ganglionic eminence	UBERON:0004023	38.78	gold quality
stromal cell of endometrium	CL:0002255	38.75	gold quality
leukocyte	CL:0000738	38.17	gold quality
monocyte	CL:0000576	38.13	gold quality
right testis	UBERON:0004534	37.42	gold quality
skeletal muscle tissue	UBERON:0001134	37.41	gold quality
testis	UBERON:0000473	37.19	gold quality
duodenum	UBERON:0002114	36.85	gold quality
ventricular zone	UBERON:0003053	36.48	gold quality
left testis	UBERON:0004533	36.02	gold quality
calcaneal tendon	UBERON:0003701	35.79	gold quality
bone marrow	UBERON:0002371	35.64	gold quality
liver	UBERON:0002107	35.51	silver quality
granulocyte	CL:0000094	35.50	gold quality
blood	UBERON:0000178	35.39	silver quality
C1 segment of cervical spinal cord	UBERON:0006469	34.03	gold quality
muscle tissue	UBERON:0002385	34.02	gold quality
mucosa of transverse colon	UBERON:0004991	33.83	gold quality
superior frontal gyrus	UBERON:0002661	33.13	gold quality
prefrontal cortex	UBERON:0000451	32.51	gold quality
lymph node	UBERON:0000029	29.73	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.78

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 2)

• Experiments performed using mice, but the observations maybe relevant to other organisms as well. (PMID:18522874)
• Results verify IRX1, EBF3, SLC5A8, SEPT9, and FUSSEL18 as valid methylation markers in two separate sets of HNSCC specimens; also preliminarily show a trend between HPV16 positivity and target gene hypermethylation of IRX1, EBF3, SLC5A8, and SEPT9. (PMID:20029986)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	skor2	ENSDARG00000063614
mus_musculus	Skor2	ENSMUSG00000091519
rattus_norvegicus	Skor2	ENSRNOG00000018006

Paralogs (3): SKIL (ENSG00000136603), SKI (ENSG00000157933), SKOR1 (ENSG00000188779)

Protein

Protein identifiers

SKI family transcriptional corepressor 2 — Q2VWA4 (reviewed: Q2VWA4)

Alternative names: Functional Smad-suppressing element on chromosome 18, LBX1 corepressor 1-like protein, Ladybird homeobox corepressor 1-like protein

All UniProt accessions (1): Q2VWA4

UniProt curated annotations — full annotation on UniProt →

Function. Exhibits transcriptional repressor activity. Acts as a TGF-beta antagonist in the nervous system.

Subunit / interactions. Interacts with SMAD2 and SMAD3.

Subcellular location. Nucleus. Cytoplasm.

Tissue specificity. Expressed in cerebellum, spinal cord and testis. Isoform 2 is present in cerebellum (at protein level).

Similarity. Belongs to the SKI family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q2VWA4-1	1	yes
Q2VWA4-2	2

RefSeq proteins (2): NP_001032891, NP_001264992* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003380	SKI/SNO/DAC	Domain
IPR009061	DNA-bd_dom_put_sf	Homologous_superfamily
IPR010919	SAND-like_dom_sf	Homologous_superfamily
IPR014890	c-SKI_SMAD4-bd_dom	Domain
IPR023216	Tscrpt_reg_SKI_SnoN	Family
IPR037000	Ski_DNA-bd_sf	Homologous_superfamily

Pfam: PF02437, PF08782

UniProt features (19 total): compositionally biased region 13, region of interest 2, splice variant 2, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q2VWA4-F1	52.95	0.13

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 75 (showing top): GOBP_DENDRITE_DEVELOPMENT, GOBP_HINDBRAIN_DEVELOPMENT, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, GOBP_METENCEPHALON_DEVELOPMENT, GOBP_REGULATION_OF_DENDRITE_MORPHOGENESIS, GOBP_CEREBELLAR_PURKINJE_CELL_LAYER_FORMATION, GOBP_CEREBELLAR_CORTEX_MORPHOGENESIS, GOBP_NEUROGENESIS, GOBP_NEURAL_PRECURSOR_CELL_PROLIFERATION, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION, GOBP_CEREBELLAR_CORTEX_DEVELOPMENT, GOBP_REGULATION_OF_TRANSMEMBRANE_RECEPTOR_PROTEIN_SERINE_THREONINE_KINASE_SIGNALING_PATHWAY, GOBP_RESPONSE_TO_TRANSFORMING_GROWTH_FACTOR_BETA, GOBP_DENDRITE_MORPHOGENESIS

GO Biological Process (13): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of DNA-templated transcription (GO:0006355), smoothened signaling pathway (GO:0007224), cerebellar Purkinje cell differentiation (GO:0021702), regulation of cerebellar granule cell precursor proliferation (GO:0021936), negative regulation of transforming growth factor beta receptor signaling pathway (GO:0030512), negative regulation of BMP signaling pathway (GO:0030514), positive regulation of smoothened signaling pathway (GO:0045880), cell development (GO:0048468), regulation of dendrite morphogenesis (GO:0048814), regulation of neuroblast proliferation (GO:1902692), cerebellum morphogenesis (GO:0021587), negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway (GO:0090101)

GO Molecular Function (6): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), chromatin binding (GO:0003682), histone deacetylase binding (GO:0042826), SMAD binding (GO:0046332), sequence-specific double-stranded DNA binding (GO:1990837)

GO Cellular Component (3): nucleus (GO:0005634), transcription regulator complex (GO:0005667), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase II	2
regulation of neural precursor cell proliferation	2
negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
cell surface receptor signaling pathway	1
cell differentiation in hindbrain	1
cerebellar Purkinje cell layer formation	1
central nervous system neuron differentiation	1
cerebellar granule cell precursor proliferation	1
transforming growth factor beta receptor signaling pathway	1
regulation of transforming growth factor beta receptor signaling pathway	1
BMP signaling pathway	1
regulation of BMP signaling pathway	1
negative regulation of cellular response to growth factor stimulus	1
smoothened signaling pathway	1
regulation of smoothened signaling pathway	1
positive regulation of signal transduction	1
cell differentiation	1
anatomical structure development	1
cellular developmental process	1
regulation of anatomical structure morphogenesis	1
dendrite morphogenesis	1
regulation of dendrite development	1
neuroblast proliferation	1
anatomical structure morphogenesis	1
cerebellum development	1
hindbrain morphogenesis	1
cell surface receptor protein serine/threonine kinase signaling pathway	1
negative regulation of signal transduction	1
regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
binding	1
enzyme binding	1

Protein interactions and networks

STRING

640 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SKOR2	LOXHD1	Q8IVV2	591
SKOR2	KIRREL2	Q6UWL6	536
SKOR2	TMC2	Q8TDI7	490
SKOR2	ARK2C	Q6ZSG1	466
SKOR2	MYO3A	Q8NEV4	457
SKOR2	PTF1A	Q7RTS3	449
SKOR2	UBXN11	Q5T124	443
SKOR2	LHX5	Q9H2C1	419
SKOR2	SLC5A8	Q8N695	417
SKOR2	TNNC2	P02585	414
SKOR2	CAB39L	Q9H9S4	406
SKOR2	HDHD2	Q9H0R4	404
SKOR2	IRX1	P78414	396
SKOR2	TATDN3	Q17R31	393
SKOR2	SEPTIN9	Q9UHD8	391

IntAct

0 interactions, top by confidence:

BioGRID (2): SKOR2 (Affinity Capture-MS), SKOR2 (Affinity Capture-MS)

ESM2 similar proteins: A2A9A2, A6QQ94, A6YP92, A7MB54, B5RHS5, E9PZZ1, M0R6D8, O02786, O08934, O09029, O35085, P13297, P28360, P46153, P50548, P78413, P78414, P78415, P81067, P81068, P84550, P97830, Q12952, Q13207, Q14549, Q14774, Q2VL76, Q2VL77, Q2VL78, Q2VL79, Q2VL80, Q2VL82, Q2VL83, Q2VL84, Q2VL85, Q2VL86, Q2VL87, Q2VL88, Q2VWA4, Q5SQQ9

Diamond homologs: A7M7C7, P12755, P12757, P17863, P49140, P84550, P84551, Q02225, Q1LXZ9, Q2VWA4, Q5R431, Q60665, Q60698, Q8BX46, Q9TUG2, Q925Q8, Q96NX9, H2KY91, Q9QYB2, Q9UI36

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

8 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	5
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (5)

Variant ID	HGVS	Classification
3255369	NM_001278063.4(SKOR2):c.374G>C (p.Arg125Pro)	Pathogenic
3602131	NM_001278063.4(SKOR2):c.1271_1274del (p.Lys424fs)	Pathogenic
4526337	NM_001278063.4(SKOR2):c.2750C>G (p.Ser917Ter)	Pathogenic
4526338	R125P	Pathogenic
4526339	SKOR2, 4-BP DEL, NT1271	Pathogenic

SpliceAI

413 predictions. Top by Δscore:

Variant	Effect	Δscore
18:47245560:CT:C	acceptor_gain	0.9800
18:47246570:CAT:C	donor_gain	0.9700
18:47246719:T:TA	donor_gain	0.9600
18:47245564:G:C	acceptor_gain	0.9500
18:47248225:T:TA	donor_gain	0.9500
18:47245562:C:CC	acceptor_gain	0.9400
18:47245566:G:C	acceptor_gain	0.9400
18:47246569:A:AC	donor_gain	0.9400
18:47246570:C:CC	donor_gain	0.9400
18:47246572:T:TA	donor_gain	0.9400
18:47244978:CTTAT:C	acceptor_gain	0.9200
18:47245566:G:GC	acceptor_gain	0.9200
18:47244902:GCCTA:G	donor_loss	0.9000
18:47244903:CCTA:C	donor_loss	0.9000
18:47244904:CTAC:C	donor_loss	0.9000
18:47244905:TA:T	donor_loss	0.9000
18:47244906:AC:A	donor_loss	0.9000
18:47244907:CCTGA:C	donor_loss	0.9000
18:47244908:C:A	donor_loss	0.9000
18:47231461:CA:C	acceptor_gain	0.8900
18:47231463:C:CC	acceptor_gain	0.8800
18:47244983:C:CC	acceptor_gain	0.8800
18:47246542:G:C	donor_gain	0.8700
18:47246569:ACAT:A	donor_gain	0.8700
18:47246570:CATC:C	donor_gain	0.8700
18:47246570:CATCT:C	donor_gain	0.8700
18:47246647:G:A	donor_gain	0.8700
18:47244901:AGCCT:A	donor_loss	0.8600
18:47244980:TATCT:T	acceptor_loss	0.8600
18:47244982:TCTA:T	acceptor_loss	0.8600

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000015019 (18:47238750 G>A,C), RS1000068989 (18:47215268 T>C), RS1000286259 (18:47248241 C>A,T), RS1000339164 (18:47248358 G>A), RS1000470300 (18:47212222 T>G), RS1000494319 (18:47238425 C>T), RS1000498880 (18:47233640 A>G), RS1000607932 (18:47235700 G>C), RS1000676209 (18:47219449 G>A), RS1000726031 (18:47228329 C>T), RS1000820901 (18:47226229 G>A,T), RS1000960044 (18:47213448 T>A), RS1001093992 (18:47239939 T>C), RS1001141283 (18:47252853 T>A), RS1001158615 (18:47228680 G>A)

Disease associations

OMIM: gene MIM:617138 | disease phenotypes: MIM:621386

GenCC curated gene-disease

Disease	Classification	Inheritance
nervous system disorder	Limited	Autosomal recessive

Mondo (2): Valence-Farazi cerebellar ataxia syndrome (MONDO:0980707), nervous system disorder (MONDO:0005071)

Orphanet (0):

HPO phenotypes

24 total (24 of 24 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000166	Severe periodontitis
HP:0000486	Strabismus
HP:0000639	Nystagmus
HP:0001251	Ataxia
HP:0001252	Hypotonia
HP:0001256	Mild intellectual disability
HP:0001260	Dysarthria
HP:0001263	Global developmental delay
HP:0001321	Cerebellar hypoplasia
HP:0001328	Specific learning disability
HP:0001374	Congenital hip dislocation
HP:0002066	Gait ataxia
HP:0002312	Clumsiness
HP:0002599	Head titubation
HP:0002650	Scoliosis
HP:0002749	Osteomalacia
HP:0003623	Neonatal onset
HP:0007033	Cerebellar dysplasia
HP:0007074	Thick corpus callosum
HP:0012110	Hypoplasia of the pons
HP:0012877	Retrograde ejaculation
HP:0031936	Delayed ability to walk
HP:0040010	Small posterior fossa

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST000880_14	Menarche (age at onset)	2.000000e-13
GCST002541_115	Menarche (age at onset)	8.000000e-20
GCST003993_32	Menarche (age at onset)	1.000000e-11
GCST007576_215	Chronotype	3.000000e-08
GCST007742_31	Iris heterochromicity	8.000000e-06
GCST010136_31	Fruit consumption	2.000000e-14
GCST011494_81	Daytime nap	2.000000e-44
GCST012227_711	Hip circumference adjusted for BMI	3.000000e-08
GCST90000047_229	Age at first sexual intercourse	2.000000e-11

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0004703	age at menarche
EFO:0008328	chronotype measurement
EFO:0009764	eye colour measurement
EFO:0008111	diet measurement
EFO:0007828	daytime rest measurement
EFO:0008039	BMI-adjusted hip circumference
EFO:0009749	age at first sexual intercourse measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D009422	Nervous System Diseases	C10

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs9952628	SKOR2		0.00	0

CTD chemical–gene interactions

5 total (human), top 5 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
abrine	increases expression	1
Resveratrol	decreases expression, affects cotreatment	1
Cadmium	decreases expression, increases abundance	1
Plant Extracts	affects cotreatment, decreases expression	1
Cadmium Chloride	decreases expression, increases abundance	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00560157	PHASE4	COMPLETED	Nutritional and Metabolic Evaluation of a Tube Feeding Immune Enhancing Diet in ICU Patients
NCT01319643	PHASE4	UNKNOWN	Normal Oxygenation Versus Hyperoxia in the Intensive Care Unit (ICU)
NCT01662414	PHASE4	COMPLETED	Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson’s Disease
NCT04289142	PHASE4	RECRUITING	Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients
NCT04386525	PHASE4	UNKNOWN	Omega 3 and Ischemic Stroke; Fish Oil as an Option
NCT04871464	PHASE4	UNKNOWN	Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson’s Disease
NCT04970667	PHASE4	COMPLETED	Flupentixol and Melitracen Tablets in the Treatment of Emotional Disorder
NCT05068349	PHASE4	UNKNOWN	For Patients With Ischemic Stroke, Clinically Study the Effectiveness and Safety of Butylphthalide.
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT06382467	PHASE4	UNKNOWN	Comparison of Remimazolam and Propofol Combination vs. Propofol in IOM
NCT06406127	PHASE4	RECRUITING	Effect of Alpha Lipoic Acid on Chemotherapy Induced Neurological Changes in Breast Cancer Patients
NCT00240695	PHASE3	COMPLETED	A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment
NCT01313299	PHASE3	COMPLETED	Dysport® Adult Upper Limb Spasticity
NCT01313312	PHASE3	COMPLETED	Dysport® Adult Upper Limb Spasticity Extension Study
NCT01425983	PHASE3	COMPLETED	Dietary Intervention of Stress-Induced Neurovegetative Disorders With a Specific Amino Acid Composition (asn01)
NCT01589289	PHASE3	COMPLETED	Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC
NCT01826487	PHASE3	COMPLETED	Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
NCT01862640	PHASE3	COMPLETED	A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer’s Agitation
NCT01922258	PHASE3	COMPLETED	Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer’s Type
NCT02090959	PHASE3	TERMINATED	An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy
NCT02284126	PHASE3	COMPLETED	Topical Vancomycin for Neurosurgery Wound Prophylaxis
NCT02436096	PHASE3	COMPLETED	A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
NCT02770807	PHASE3	COMPLETED	Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients
NCT02829814	PHASE3	TERMINATED	Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
NCT03179631	PHASE3	COMPLETED	Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
NCT03336450	PHASE3	COMPLETED	Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting
NCT03336645	PHASE3	COMPLETED	Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan
NCT04639310	PHASE3	TERMINATED	XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
NCT04912856	PHASE3	TERMINATED	An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
NCT05126758	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
NCT05361707	PHASE3	UNKNOWN	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05508789	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ 5)
NCT05738486	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer’s Disease (TRAILBLAZER-ALZ 6)
NCT05834855	PHASE3	RECRUITING	Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
NCT06672237	PHASE3	RECRUITING	A Phase 3 Study of NTLA-2001 in ATTRv-PN
NCT06819592	PHASE3	RECRUITING	PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury
NCT07587242	PHASE3	NOT_YET_RECRUITING	A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
NCT00659776	PHASE2	TERMINATED	MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation
NCT01059149	PHASE2	TERMINATED	Safety and Long-term Effectiveness of High Frequency Repetitive Transcranial Magnetic Stimulation of Stroke (RAICup)
NCT01255358	PHASE2	COMPLETED	Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients